

CITATION REPORT

List of articles citing

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

DOI: 10.1001/jamaneurol.2016.6117
JAMA Neurology, 2017, 74, 557-566.

Source: <https://exaly.com/paper-pdf/66636014/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
550	Alzheimer disease: Neurofilament light in the blood marks Alzheimer degeneration. 2017 , 13, 257		2
549	Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. 2017 , 1668, 12-19		36
548	Potential biomarker breakthrough for Huntington's disease. 2017 , 16, 573-574		
547	Searching for Neurodegeneration in the Blood of Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2017 , 74, 510-511	17.2	1
546	Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. 2017 , 89, 2167-2175		154
545	Neurofilaments in blood: (Almost) facing clinical application. 2017 , 89, 2126-2127		
544	A systemic view of Alzheimer disease - insights from amyloid- β metabolism beyond the brain. 2017 , 13, 612-623		356
543	Prion-like transmission of β -synuclein pathology in the context of an NFL null background. 2017 , 661, 114-120		2
542	Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study. 2017 , 60, 1411-1427		28
541	Serum neurofilament light is sensitive to active cerebral small vessel disease. 2017 , 89, 2108-2114		96
540	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. 2017 , 23, 1600-1613		22
539	A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. 2017 , 6, 15-24		141
538	Visual Dysfunction in Posterior Cortical Atrophy. 2017 , 8, 389		25
537	Innovative Biomarkers for Alzheimer's Disease: Focus on the Hidden Disease Biomarkers. 2018 , 62, 1507-1518		16
536	Neurofilament as Neuronal Injury Blood Marker in Preeclampsia. 2018 , 71, 1178-1184		19
535	Neurofilament light and tau as blood biomarkers for sports-related concussion. 2018 , 90, e1780-e1788		90
534	Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. 2018 , 35, 2351-2356		27

533	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. 2018 , 14, 535-562	3155
532	Association of Plasma Neurofilament Light Chain with Neocortical Amyloid- β Load and Cognitive Performance in Cognitively Normal Elderly Participants. 2018 , 63, 479-487	30
531	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. 2018 , 14, 563-575	61
530	The Past and the Future of Alzheimer's Disease Fluid Biomarkers. 2018 , 62, 1125-1140	69
529	Precision pharmacology for Alzheimer's disease. 2018 , 130, 331-365	60
528	Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments. 2018 , 151, 291-306	20
527	Progress and Challenges in the Diagnosis of Dementia: A Critical Review. 2018 , 9, 446-461	16
526	Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. 2018 , 90, e518-e524	107
525	CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. 2018 , 265, 510-521	51
524	Rapidly Progressive Alzheimer's Disease: Contributions to Clinical-Pathological Definition and Diagnosis. 2018 , 63, 887-897	11
523	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. 2018 , 10, 8	62
522	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. 2018 , 10, 30	29
521	Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. 2018 , 221-252	1
520	Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. 2018 , 10, 172-181	13
519	2018 Alzheimer's disease facts and figures. 2018 , 14, 367-429	1154
518	ABCA7 genotype altered A β levels in cerebrospinal fluid in Alzheimer's disease without dementia. 2018 , 6, 437	6
517	Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. 2018 , 8, 17368	103
516	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. 2018 , 10, 113	38

515	Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury. 2018 , 9, 984	6
514	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. 2018 , 4, 703-713	41
513	Current state of Alzheimer's fluid biomarkers. 2018 , 136, 821-853	236
512	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. 2018 , 14, 639-652	257
511	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. 2018 , 60, 13-25	7
510	Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. 2018 , 5, 1478-1491	69
509	Serum neurofilament light chain in behavioral variant frontotemporal dementia. 2018 , 91, e1390-e1401	51
508	Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias. 2018 , 6,	33
507	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. 2018 , 17, 860-869	105
506	Diagnostic biomarkers of Alzheimer's disease in Down syndrome. 2018 , 17, 831-832	0
505	Neurofilaments as biomarkers in neurological disorders. 2018 , 14, 577-589	627
504	Blood biomarkers in Alzheimer's disease. 2018 ,	2
503	Neurofilament relates to white matter microstructure in older adults. 2018 , 70, 233-241	34
502	Clinical Research on Alzheimer's Disease: Progress and Perspectives. 2018 , 34, 1111-1118	64
501	Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. 2018 , 91, e436-e443	25
500	Biomarkers for Alzheimer's disease: current status and prospects for the future. 2018 , 284, 643-663	278
499	Alzheimer's disease and blood-based biomarkers - potential contexts of use. 2018 , 14, 1877-1882	19
498	Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. 2018 , 10, 71	141

497	The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. 2018 , 10, 3	57
496	Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. 2018 , 10, 39	37
495	Genome-wide association study identifies two loci influencing plasma neurofilament light levels. 2018 , 11, 47	9
494	Blood-based near-infrared spectroscopy for the rapid low-cost detection of Alzheimer's disease. 2018 , 143, 5959-5964	18
493	Raman Spectroscopy to Diagnose Alzheimer's Disease and Dementia with Lewy Bodies in Blood. 2018 , 9, 2786-2794	38
492	Update on biomarkers for amyloid pathology in Alzheimer's disease. 2018 , 12, 799-812	39
491	Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid- β load: A pilot study. 2018 , 8, 8008	28
490	Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. 2019 , 45, 291-304	55
489	Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. 2019 , 46, 228-235	5
488	Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses. 2019 , 79, 684-698	14
487	[New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood]. 2019 , 90, 907-913	1
486	Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions. 2019 ,	14
485	Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. 2019 , 11, 175	59
484	Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric A β and Tau Species. 2019 , 13, 659	122
483	Primary fatty amides are potential plasma biomarkers for AD. 2019 , 15, 498-499	
482	Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases. 2019 , 20,	25
481	Plasma neurofilament light chain and amyloid- β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. 2019 , 16, 186	28
480	. 2019 ,	0

479	The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. 2019 , 11, 730-743		46
478	Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. 2019 , 15, 1437-1447		20
477	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. 2019 , 11, e11170		113
476	Plasma Neurofilament Light Chain in Primary Progressive Aphasia and Related Disorders: Clinical Significance and Metabolic Correlates. 2019 , 72, 773-782		7
475	Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. 2019 , 11, 700-709		15
474	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. 2019 , 7, 5		79
473	The "rights" of precision drug development for Alzheimer's disease. 2019 , 11, 76		93
472	NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke. 2019 , 50, 3077-3084		51
471	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. 2019 , 11, 679-689		31
470	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. 2019 , 25, 277-283		375
469	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. 2019 , 67, 481-488		79
468	AD molecular: Molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems. 2019 , 165, 139-165		3
467	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β Amyloid Status. <i>JAMA Neurology</i> , 2019 , 76, 1060-1069	17.2	159
466	Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. 2019 , 6, 169-173		23
465	Potential Value of Plasma Amyloid- β Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease. 2019 , 10, 3479-3485		26
464	Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. 2019 , 93, e252-e260		81
463	A frontline defense against neurodegenerative diseases:the development of early disease detection methods. 2019 , 19, 559-563		8
462	Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2019 , 76, 969-977	17.2	39

461	Current and Developing Methods for Diagnosing Alzheimer's Disease. 2019 , 43-87	2
460	Observational study of long-term persistent elevation of neurodegeneration markers after cardiac surgery. 2019 , 9, 7177	13
459	Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. 2019 , 5, 129-138	16
458	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2019 , 76, 791-799	17.2 228
457	Neurofilament as a potential biomarker for spinal muscular atrophy. 2019 , 6, 932-944	76
456	Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis. 2019 , 102, 123-138	32
455	Effects of CD33 Variants on Neuroimaging Biomarkers in Non-Demented Elders. 2019 , 68, 757-766	3
454	Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders. 2019 , 25, 673-685	18
453	Revealing heterogeneity of brain imaging phenotypes in Alzheimer's disease based on unsupervised clustering of blood marker profiles. 2019 , 14, e0211121	6
452	Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries. 2019 , 36, 2400-2406	16
451	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. 2019 , 11, 26	43
450	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. 2019 , 15, 742-753	50
449	Alzheimer's Disease-related Biomarkers in Aging Adults with Down Syndrome: Systematic Review. 2019 , 15, 49-57	1
448	Neurofilament light chain as a biomarker in neurological disorders. 2019 , 90, 870-881	250
447	Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. 2019 , 10, 310	23
446	Blood-based molecular biomarkers for Alzheimer's disease. 2019 , 12, 26	100
445	Search for biomarkers of Alzheimer's disease: Recent insights, current challenges and future prospects. 2019 , 72, 39-51	13
444	Neurofilament Light Chain as a Biomarker in Multiple Sclerosis. 2019 , 10, 338	59

443	Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients. 2019 , 14, e0211575	16
442	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. 2019 , 113, 137-140	40
441	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. 2019 , 11, 19	47
440	Coimmunocapture and Electrochemical Quantitation of Total and Phosphorylated Amyloid- β Monomers. 2019 , 91, 3539-3545	10
439	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. 2019 , 5, eaau7220	44
438	Early Diagnosis of Alzheimer's Disease. 2019 , 7-12	
437	The Influence of BDNF Val66Met Polymorphism on Cognition, Cerebrospinal Fluid, and Neuroimaging Markers in Non-Demented Elderly. 2019 , 68, 405-414	5
436	Delirium and Alzheimer disease: A proposed model for shared pathophysiology. 2019 , 34, 781-789	23
435	The Role of Biomarkers in Alzheimer's Disease Drug Development. 2019 , 1118, 29-61	40
434	Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer's disease. 2019 , 5, 94-105	3
433	The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey. 2019 , 32, 931-940	6
432	A Brief Review of Paradigm Shifts in Prevention of Alzheimer's Disease: From Cognitive Reserve to Precision Medicine. 2019 , 10, 786	4
431	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. 2019 , 11, 94	15
430	Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. 2019 , 168, 3-23	11
429	Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis. 2019 , 72, 1353-1361	22
428	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease. 2019 , 12, 1756286419888819	
427	Precision Medicine: Role of Biomarkers in Early Prediction and Diagnosis of Alzheimer's Disease. 2019 ,	2
426	Neurofilament light is a treatment-responsive biomarker in CLN2 disease. 2019 , 6, 2437-2447	12

425	CADASIL: new advances in basic science and clinical perspectives. 2019 , 26, 193-198	15
424	Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. 2019 , 7,	55
423	An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform. 2019 , 8, 73-82	37
422	Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in. 2019 , 8, 37	11
421	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. 2019 , 14, e0226276	6
420	Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. 2019 , 33, 99-106	24
419	Multiple sclerosis in 2018: new therapies and biomarkers. 2019 , 18, 10-12	10
418	Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. 2019 , 698, 58-63	37
417	Diagnostic and prognostic biomarkers for HAND. 2019 , 25, 686-701	9
416	Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease. 2019 , 25, 702-709	89
415	Blood-based biomarkers for Alzheimer's disease-An update. 2019 , 319, 2-6	55
414	CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. 2019 , 74, 182-190	33
413	Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. <i>JAMA Neurology</i> , 2019 , 76, 64-71	17.2 85
412	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. 2019 , 90, 157-164	113
411	Biomarkers for tau pathology. 2019 , 97, 18-33	96
410	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?. 2020 , 54, 57-67	18
409	Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases. 2020 , 46, 240-254	15
408	Serum NFL levels should be used to monitor multiple sclerosis evolution - No. 2020 , 26, 19-21	4

407	Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. 2020 , 267, 162-167	36
406	Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. 2020 , 141, 16-21	14
405	Human Tridimensional Neuronal Cultures for Phenotypic Drug Screening in Inherited Peripheral Neuropathies. 2020 , 107, 1231-1239	6
404	Serum Raman spectroscopy as a diagnostic tool in patients with Huntington's disease. 2020 , 11, 525-533	10
403	Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnesic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial). 2020 , 21, 19	1
402	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. 2020 , 88, 83-90	3
401	Single-molecule measurements in microwells for clinical applications. 2019 , 1-21	12
400	Biomarkers of Alzheimer Disease. 2020 , 5, 194-208	13
399	CSF or serum neurofilament light added to β synuclein panel discriminates Parkinson's from controls. 2020 , 35, 288-295	28
398	Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease. 2020 , 12, 3	10
397	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. 2020 , 94, e30-e41	13
396	Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers. 2020 , 5, 158-169	7
395	Longitudinal change in regional brain volumes with exposure to repetitive head impacts. 2020 , 94, e232-e240	14
394	Neurofilament Light Chain as A Biomarker for Brain Metastases. 2020 , 12,	10
393	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. 2020 , 143, 3234-3241	63
392	Thirty years after anorexia nervosa onset, serum neurofilament light chain protein concentration indicates neuronal injury. 2021 , 30, 1907-1915	4
391	Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients. 2020 , 12, 272	3
390	Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia. 2020 , 12, e12104	11

389	Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease. 2020 , 40, 289-303	1
388	Simplified Digital Enzyme-Linked Immunosorbent Assay Using Tyramide Signal Amplification and Fibrin Hydrogels. 2020 , 5, 3037-3042	12
387	Research and progress on biomarkers of neuromyelitis optica spectrum disorders. 2021 , 41, 417-424	4
386	Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. 2021 , 159, 389-402	7
385	Serum neurofilament light as a biomarker in progressive multiple sclerosis. 2020 , 95, 436-444	44
384	Molecular and Imaging Biomarkers in Alzheimer's Disease: A Focus on Recent Insights. 2020 , 10,	14
383	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. 2020 , 10,	10
382	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. 2020 , 143, 3793-3804	20
381	Sleep, 24-h activity rhythms, and plasma markers of neurodegenerative disease. 2020 , 10, 20691	2
380	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. 2020 , 12, 147	8
379	Late-onset vs nonmendelian early-onset Alzheimer disease: A distinction without a difference?. 2020 , 6, e512	24
378	Comparison of neurofilament light chain results between two independent facilities. 2020 , 2, e000063	5
377	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. 2020 , 57, 4667-4691	14
376	Metallic Woodpile Nanostructures for Femtomolar Sensing of Alzheimer's Neurofilament Lights. 2020 , 14, 10376-10384	5
375	Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease. 2020 , 10,	4
374	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. 2020 , 324, 772-781	268
373	Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. 2020 , 396, 413-446	1387
372	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. 2020 , 95, 143-153	17

371	Circulating Neurofilament Light Chain Is Associated With Survival After Pediatric Cardiac Arrest. 2020 , 21, 656-661	4
370	ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. 2020 , 140, 449-461	3
369	Tracking the potential involvement of metabolic disease in Alzheimer's disease-Biomarkers and beyond. 2020 , 154, 51-77	3
368	Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage. 2020 , 78, 265-276	15
367	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. 2020 , 41, 1023-1037	15
366	CSF Neurofilament Light Chain Elevation Predicts ALS Severity and Progression. 2020 , 11, 919	2
365	Elevated plasma neurofilament light in aging reflects brain white-matter alterations but does not predict cognitive decline or Alzheimer's disease. 2020 , 12, e12050	8
364	Verbal memory dysfunction is associated with alterations in brain transcriptome in dominant temporal lobe epilepsy. 2020 , 61, 2203-2213	1
363	Neurofilament light chain in the vitreous humor of the eye. 2020 , 12, 111	4
362	The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys. 2020 , 12, e12069	4
361	The pathway to secondary prevention of Alzheimer's disease. 2020 , 6, e12069	1
360	Fluid Biomarkers for Synaptic Dysfunction and Loss. 2020 , 15, 1177271920950319	23
359	Potential human transmission of amyloid β pathology: surveillance and risks. 2020 , 19, 872-878	23
358	Longitudinal atrophy in early Braak regions in preclinical Alzheimer's disease. 2020 , 41, 4704-4717	15
357	Association of serum neurofilament light and disease severity in patients with spinocerebellar ataxia type 3. 2020 , 95, e2977-e2987	5
356	Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study. 2020 , 88, 1065-1076	26
355	Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease. 2020 , 88, 878-892	8
354	Chronic Traumatic Encephalopathy: A Comparison with Alzheimer's Disease and Frontotemporal Dementia. 2020 , 40, 394-410	3

353	Associations of Green Tea Consumption and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. 2020 , 77, 411-421	3
352	Renal function is associated with blood neurofilament light chain level in older adults. 2020 , 10, 20350	26
351	Neurofilament light chain level in plasma extracellular vesicles and Parkinson's disease. 2020 , 13, 1756286420975917	
350	Raised Plasma Neurofilament Light Protein Levels After Rewarming Are Associated With Adverse Neurodevelopmental Outcomes in Newborns After Therapeutic Hypothermia. 2020 , 11, 562510	0
349	APOE ϵ/ϵ homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. 2020 , 6, e12117	2
348	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. 2020 , 11, 6252	15
347	Biomarkers: Our Path Towards a Cure for Alzheimer Disease. 2020 , 15, 1177271920976367	9
346	Elevated Levels of Serum Neurofilament Light Chain Associated with Cognitive Impairment in Vascular Dementia. 2020 , 2020, 6612871	3
345	Blood neurofilament light: a critical review of its application to neurologic disease. 2020 , 7, 2508-2523	39
344	Blood biomarkers in Alzheimer's disease. 2021 , 36, 704-710	7
343	Plasma Neurofilament Light and Longitudinal Progression of White Matter Hyperintensity in Elderly Persons Without Dementia. 2020 , 75, 729-737	7
342	A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. 2020 , 94, 60-70	13
341	Relevance of biomarkers across different neurodegenerative diseases. 2020 , 12, 56	15
340	Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. 2020 , 7,	14
339	Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. 2020 , 21,	4
338	Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. 2020 , 10, 7995	11
337	Neurofilaments: neurobiological foundations for biomarker applications. 2020 , 143, 1975-1998	56
336	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. 2020 , 19, 513-521	53

335	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. 2020 , 94, e2457-e2467	29
334	Temporal association of sNFL and gad-enhancing lesions in multiple sclerosis. 2020 , 7, 945-955	15
333	Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology. 2020 , 15, e0234519	3
332	Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value. 2020 , 14, 579	15
331	The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. 2020 , 12, 74	18
330	Risk Factors for Delayed Neurocognitive Recovery According to Brain Biomarkers and Cerebral Blood Flow Velocity. 2020 , 56,	0
329	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. 2020 , 18, 140	16
328	The CNS-specific proteoglycan, brevican, and its ADAMTS4-cleaved fragment show differential serological levels in Alzheimer's disease, other types of dementia and non-demented controls: A cross-sectional study. 2020 , 15, e0234632	3
327	Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. 2020 , 17, 86	23
326	Biochemical Markers in Alzheimer's Disease. 2020 , 21,	24
325	Neurofilaments in disease: what do we know?. 2020 , 61, 105-115	17
324	Molecular biomarkers in the neurological ICU: is there a role?. 2020 , 26, 103-108	0
323	Plasma tau, neurofilament light chain and amyloid- β levels and risk of dementia; a population-based cohort study. 2020 , 143, 1220-1232	90
322	Presymptomatic Increase of an Extracellular RNA in Blood Plasma Associates with the Development of Alzheimer's Disease. 2020 , 30, 1771-1782.e3	15
321	Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local β -Amyloid, Tau, and APOE4. 2020 , 12, 46	8
320	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. 2020 , 12, e12005	17
319	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. 2020 ,	8
318	Blood biomarkers of traumatic brain injury and cognitive impairment in older veterans. 2020 , 95, e1126-e1133	24

317	Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment. 2020 , 76, 1017-1027	39
316	Phenotypic bases of NOTCH2NLC GGC expansion positive neuronal intranuclear inclusion disease in a Southeast Asian cohort. 2020 , 98, 274-281	10
315	Neurofilament light as a biomarker in traumatic brain injury. 2020 , 95, e610-e622	41
314	Blood and cerebrospinal fluid biomarkers for Alzheimer's disease. 2020 , 5, 15-15	2
313	Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. 2020 , 49, 5446-5472	25
312	Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration. 2020 , 41, 281-293	38
311	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. 2020 , 20, 421-441	19
310	Association of serum biomarker neurofilament light concentration with post-stroke depression: A preliminary study. 2020 , 64, 17-25	11
309	Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. 2020 , 80, 291-295	31
308	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. 2020 , 12, 20	13
307	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. 2020 , 73, 1585-1595	10
306	Neurofilaments: The C-Reactive Protein of Neurology. 2020 , 10,	19
305	Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease. 2020 , 4, 21-37	15
304	Leveraging preclinical models for the development of Alzheimer disease therapeutics. 2020 , 19, 447-462	37
303	Anti-neurofilament antibodies and neurodegeneration: Markers and generators. 2020 , 344, 577248	2
302	Neurofilament-light in former athletes: a potential biomarker of neurodegeneration and progression. 2020 , 27, 1170-1177	4
301	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. 2020 , 16, 265-284	53
300	New fluid biomarkers tracking non-amyloid- β and non-tau pathology in Alzheimer's disease. 2020 , 52, 556-568	34

299	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. 2021 , 185, 108081	12
298	The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer's disease. 2021 , 97, 10-17	6
297	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. 2021 , 1, 114-123	34
296	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. 2021 , 144, 325-339	42
295	Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis. 2021 , 79, 177-195	9
294	The relationship between neurofilament light chain and cognition in neurological disorders: A scoping review. 2021 , 420, 117229	4
293	Utility of Plasma Neurofilament Light in the 1Florida Alzheimer's Disease Research Center (ADRC). 2021 , 79, 59-70	4
292	Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction. 2021 , 11, 107-121	12
291	Analyzing the effect of APOE on Alzheimer's disease progression using an event-based model for stratified populations. 2021 , 227, 117646	3
290	Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. 2021 , 64, 926-937	2
289	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. 2021 , 26, 429-442	70
288	Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis. 2021 , 14, 17562864211001977	0
287	Biomarcadores en la enfermedad de Alzheimer. 2021 , 2, 39-50	1
286	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. 2021 , 34, 266-274	14
285	Differential effect of ethanol intoxication on peripheral markers of cerebral injury in murine blunt traumatic brain injury. 2021 , 9, tkab027	1
284	Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. 2021 , 13, e12168	12
283	Neurofilament light is a novel biomarker for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. 2021 , 11, 2001	3
282	Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. 2021 , 265, 1-97	0

281	Nanoarchitected Bioconjugates and Bioreceptors Mediated Surface Plasmon Resonance Biosensor for Diagnosis of Alzheimer's Disease: Development and Future Prospects. 2021 , 1-31	5
280	The Potential of Neurofilament Light as a Biomarker in Alzheimer's Disease. 2021 , 84, 6-15	4
279	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. 2021 , 13, 17	11
278	Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease.	
277	Proteomic Profiling of Cerebrum Mitochondria, Myelin Sheath, and Synaptosome Revealed Mitochondrial Damage and Synaptic Impairments in Association with 3 Tg-AD Mice Model. 2021 , 1	3
276	Plasma Neurofilament Light Chain as a Predictive Biomarker for Post-stroke Cognitive Impairment: A Prospective Cohort Study. 2021 , 13, 631738	3
275	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. 2021 , 141, 709-724	83
274	Neurofilament light chain predicts future dementia risk in cerebral small vessel disease. 2021 ,	5
273	CSF and Blood Neurofilament Levels in Athletes Participating in Physical Contact Sports: A Systematic Review. 2021 , 96, 705-715	3
272	Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. 2021 , 11, e02084	7
271	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. 2021 , 17, 801-812	7
270	Biological variation of serum neurofilament light chain. 2021 ,	1
269	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. 2021 , 48, 2140-2156	31
268	Relationship of Neurofilament Light (NFL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia. 2020 , 17, 1214-1220	3
267	Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. 2021 , 13, 65	13
266	Electrochemical immunoplatfrom to unravel neurodegeneration and Alzheimer's disease through the determination of neurofilament light protein. 2021 , 371, 137815	6
265	Association of Plasma Neurofilament Light With Small Vessel Disease Burden in Nondemented Elderly: A Longitudinal Study. 2021 , 52, 896-904	8
264	Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: From preclinical models to clinical practice. 2021 , 749, 135739	5

263	Diagnose it yourself: will there be a home test kit for Alzheimer's disease?. 2021 , 11, 167-176		
262	Metabolic, Phenotypic, and Neuropathological Characterization of the Tg4-42 Mouse Model for Alzheimer's Disease. 2021 , 80, 1151-1168		3
261	Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. 2021 , 22,		5
260	Synergistic Effects of APOE and CLU May Increase the Risk of Alzheimer's Disease: Acceleration of Atrophy in the Volumes and Shapes of the Hippocampus and Amygdala. 2021 , 80, 1311-1327		4
259	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021 , 78, 396-406	17.2	41
258	State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementia-A Short Review and Diagnostic Algorithm. 2021 , 11,		4
257	Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults: The MAPT Study. 2021 , 76, 1382-1390		3
256	Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. 2021 , 268, 3835-3844		3
255	Serum Levels of Clusterin, PKR, and RAGE Correlate with Amyloid Burden in Alzheimer's Disease. 2021 , 80, 1067-1077		4
254	Association of plasma neurofilament L (NFL) levels with severity of dementia in Alzheimer's disease: An exploratory study from South India. 2021 , 58, 102606		1
253	Plasma neurofilament light chain levels predict improvement in late phase after stroke. 2021 , 28, 2218-2228		1
252	Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging. 2021 ,		8
251	Circulating Neurofilament Light Predicts Cognitive Decline in Patients With Post-stroke Subjective Cognitive Impairment. 2021 , 13, 665981		4
250	Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. 2021 , 13, 659898		3
249	Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population. 2021 , 67, 103361		6
248	A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study. 2021 , 13, 101		5
247	Biomarkers and Their Implications in Alzheimer's Disease: A Literature Review. 2021 , 000, 000-000		1
246	Recognition of Mild Cognitive Impairment in the Elderly Based on Machine Learning. 2021 ,		

245	Biomarkers and Tools for Predicting Alzheimer's Disease at the Preclinical Stage. 2021,	4
244	The Role of Plasma Neurofilament Light Protein for Assessing Cognitive Impairment in Patients With End-Stage Renal Disease. 2021, 13, 657794	2
243	Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. 2021, 22,	6
242	Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment. 2021, 1-12	5
241	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β ₂ /A β ₀ and p-tau. 2021,	12
240	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. 2021, 12, 3555	23
239	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. 2021, 290, 583-601	15
238	Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. 2021, 3, e000143	8
237	A multicentre validation study of the diagnostic value of plasma neurofilament light. 2021, 12, 3400	51
236	Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults. 2021, 11, 13394	4
235	Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer's disease. 2021, 1, 550-565	3
234	Associations of longitudinal plasma p-tau181 and NFL with tau-PET, A β PET and cognition. 2021, 92, 1289-1295	4
233	In vivo evidence that SORL1, encoding the endosomal recycling receptor SORLA, can function as a causal gene in Alzheimer's Disease.	1
232	Changes in telomere length and serum neurofilament light chain levels in female patients with chronic insomnia disorder. 2021,	1
231	Characterizing plasma NFL in a community-dwelling multi-ethnic cohort: Results from the HABLE study. 2021,	8
230	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. 2021,	5
229	Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer's Disease in the FIT-AD Trial. 2021, 5, 601-611	2
228	Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease. 2021, 13, 123	9

227	Developing the ATX(N) classification for use across the Alzheimer disease continuum. 2021 , 17, 580-589	25
226	Amyloid- β -positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. 2021 , 104, 24-31	2
225	Cognitive Impairment and Dementia After Stroke: Design and Rationale for the DISCOVERY Study. 2021 , 52, e499-e516	6
224	Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease. 2021 , 13, 718959	2
223	Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years. 2021 , 82, 951-964	1
222	Targeting autonomic flexibility to enhance cognitive training outcomes in older adults with mild cognitive impairment: study protocol for a randomized controlled trial. 2021 , 22, 560	1
221	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. 2021 , 28, 3722-3730	2
220	Sustained Axonal Degeneration in Prolonged Disorders of Consciousness. 2021 , 11,	1
219	Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum. 2021 , 140, 141-148	8
218	Plasma neurofilament light as a potential biomarker for cognitive decline in a longitudinal study of middle-aged urban adults. 2021 , 11, 436	1
217	Plasma NfL levels and longitudinal change rates in and -associated diseases: from tailored references to clinical applications. 2021 , 92, 1278-1288	2
216	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. 2021 , 20, 605-614	9
215	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. 2021 ,	9
214	Development of infrastructure for a systemic multidisciplinary approach to study aging in retired sled dogs. 2021 , 13, 21814-21837	2
213	A blood test for Alzheimer's disease: a step forward. 2021 , 20, 691-693	1
212	Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies. 2021 , 15, 689938	10
211	The blood biomarkers puzzle - A review of protein biomarkers in neurodegenerative diseases. 2021 , 361, 109281	4
210	Systematic Search for Novel Circulating Biomarkers Associated with Extracellular Vesicles in Alzheimer's Disease: Combining Literature Screening and Database Mining Approaches. 2021 , 11,	1

209	Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury. 2021 , 13, eabg9922	9
208	Blood biomarkers for the diagnosis of amnesic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. 2021 , 128, 479-486	10
207	Serum GFAP and NFL levels in benign relapsing-remitting multiple sclerosis. 2021 , 56, 103280	1
206	Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease. 2021 , 358, 577662	3
205	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. 2021 ,	11
204	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. 2021 , 92, 1231-1241	14
203	CSF neurofilament light may predict progression from amnesic mild cognitive impairment to Alzheimer's disease dementia. 2021 , 107, 78-85	3
202	Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer's pathology: Insights and therapeutic approaches from periphery. 2021 , 71, 101451	4
201	Biomarkers of Diseases: Their Role in Emergency Medicine.	
200	Sex differences in CSF biomarkers of Alzheimer's disease. 2021 , 107-123	
199	Development of a Plasma Biomarker Diagnostic Model Incorporating Ultrasensitive Digital Immunoassay as a Screening Strategy for Alzheimer Disease in a Chinese Population. 2021 , 67, 1628-1639	2
198	Blood biomarkers for dementia in Hispanic and non-Hispanic White adults. 2021 , 7, e12164	4
197	Plasma biomarkers of Alzheimer's disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly.	1
196	Early-Onset Alzheimer's Disease: What Is Missing in Research?. 2021 , 21, 4	20
195	A Workshop on Cognitive Aging and Impairment in the 9/11-Exposed Population. 2021 , 18,	5
194	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. 2020 , 12, e12099	8
193	Serum neurofilament light levels in normal aging and their association with morphologic brain changes. 2020 , 11, 812	118
192	Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. 2020 , 2, fcaa166	8

191	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease.	2
190	Single-soma transcriptomics of tangle-bearing neurons in Alzheimer's disease reveals the signatures of tau-associated synaptic dysfunction.	12
189	Time course of phosphorylated tau181 in blood across the Alzheimer's disease spectrum.	2
188	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.	1
187	Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer's disease.	0
186	Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. 2020 , 12, 118	54
185	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. 2021 , 96, e671-e683	21
184	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia. 2020 , 15, e0236384	10
183	Biomarkers in Alzheimer's disease. 2021 , 2, 27-37	2
182	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. 2020 , 42, 431-441	18
181	The Challenges of Diagnosis in Alzheimer's Disease. 2018 , 14, 15	3
180	Diagnostic performance of new and classic CSF biomarkers in age-related dementias. 2019 , 11, 2420-2429	12
179	Genome-wide association study identifies CD1A associated with rate of increase in plasma neurofilament light in non-demented elders. 2019 , 11, 4521-4535	4
178	Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. 2019 , 11, 6904-6914	18
177	Late-life obesity is a protective factor for prodromal Alzheimer's disease: a longitudinal study. 2020 , 12, 2005-2017	12
176	Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer's disease. 2020 , 12, 9365-9379	8
175	Serum neurofilament light chain rate of change in Alzheimer's disease: potentials applications and notes of caution. 2019 , 7, S133	4
174	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease?. 2019 , 21, 177-191	13

173	The Importance of Non-Coding RNAs in Neurodegenerative Processes of Diabetes-Related Molecular Pathways. 2020 , 10,	6
172	Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation. 2017 , 161, 286-295	7
171	Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden. 2018 , 20, 228-238	54
170	Serum Neurofilament Light Chain Is Associated with Incident Lacunes in Progressive Cerebral Small Vessel Disease. 2020 , 22, 369-376	11
169	Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: a case-control study. 2021 , 13, 22666-22689	1
168	Performance of Plasma Amyloid β Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China. 2021 , 13, 749649	2
167	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6. 2021 , 13, 169	10
166	Neurochemical Markers of Traumatic Brain Injury: Relevance to Acute Diagnostics, Disease Monitoring, and Neuropsychiatric Outcome Prediction. 2021 ,	3
165	Plasma Neurofilament Light (NFL) in Patients Affected by Niemann-Pick Type C Disease (NPCD). 2021 , 10,	1
164	Possible Biomarkers for Frontotemporal Dementia and to Differentiate from Alzheimer's Disease and Amyotrophic Lateral Sclerosis. 2022 , 387-403	
163	Current research status of blood biomarkers in Alzheimer's disease: Diagnosis and prognosis. 2021 , 72, 101492	4
162	Neurofilament light: a possible prognostic biomarker for treatment of vascular contributions to cognitive impairment and dementia. 2021 , 18, 236	1
161	Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome.	
160	Revealing heterogeneity of brain imaging phenotypes in Alzheimer's disease based on unsupervised clustering of blood marker profiles.	
159	A New Biological Definition of Alzheimer's Disease: Introduction of 2018 National Institute on Aging-Alzheimer's Association Research Framework. 2019 , 37, 1-7	1
158	Ruolo dei biomarcatori nella diagnostica liquorale della malattia di Alzheimer. 2019 , 15,	
157	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-A β load and cerebrospinal fluid A β in a pilot study of Alzheimer's disease. 2020 , 731, 135078	1
156	Body Mass Index and Allostatic Load are Directly Associated with Longitudinal Increase in Plasma Neurofilament Light Among Urban Middle-aged Adults. 2021 ,	0

155	Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. 2021 , 37, 67	3
154	Clinical Assessment and Intervention With Persons Living With Dementia. 2020 ,	
153	The promise of microRNA-based therapies in Alzheimer's disease: challenges and perspectives. 2021 , 16, 76	8
152	Ultrasensitive detection of blood biomarkers of Alzheimer's and Parkinson's diseases: a systematic review. 2021 , 15, 1693-1708	1
151	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia.	
150	Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment.	1
149	Differential effect of ethanol intoxication on peripheral markers of cerebral injury in murine blunt TBI.	
148	Neurofilament degradation is involved in laparotomy-induced cognitive dysfunction in aged rats. 2020 , 12, 25643-25657	1
147	Detection of Alzheimer's Disease. 2018 , 91, 291-300	17
146	Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis. 2021 , 20, 1308-1325	
145	Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen. 2021 ,	0
144	Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes.. 2021 , 9,	2
143	Neurofilament Light Chain as a Biomarker in Cerebral Small-Vessel Disease. 2021 , 1	2
142	Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease. 2021 ,	3
141	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. 2021 ,	12
140	The Neurochemistry of Alzheimer's Disease: One of the Most Common Causes of Reduced Capability in the Adult Population. 2022 , 81-93	
139	Serum neurofilament light chain level as a predictor of cognitive stage transition.. 2022 , 14, 6	2
138	Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention.. 2021 , 74, 101544	3

137	Neurofilaments light: Possible biomarker of brain modifications in bipolar disorder.. 2021 , 300, 243-248	0
136	Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia.. 2022 , 16, 758182	0
135	Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders.. 2022 , 23,	1
134	Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects. 2021 , 152, 105250	1
133	Vasulocentric Axonal NfH in Small Vessel Disease.. 2022 ,	0
132	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage.. 2022 , 105662	1
131	An Age Dependent Mathematical Model of Neurofilament Trafficking in Healthy Conditions.. 2022 ,	1
130	Correlation Between Urine Formaldehyde and Cognitive Abilities in the Clinical Spectrum of Alzheimer's Disease.. 2022 , 14, 820385	1
129	The accuracy and robustness of plasma biomarker models for amyloid PET positivity.. 2022 , 14, 26	4
128	Association of peripheral immunity with cognition, neuroimaging, and Alzheimer's pathology.. 2022 , 14, 29	0
127	Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer's Disease in Blood.. 2021 , 14, 778955	0
126	Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds.. 2022 , 14, e12295	0
125	Progress of Nanotechnology-Based Detection and Treatment of Alzheimer's Disease Biomarkers. 2022 , 47-88	
124	Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort.. 2022 , 14, e12298	0
123	Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature.. 2022 ,	2
122	Plasma neurofilament light levels correlate with white matter damage prior to Alzheimer's disease: results from ADNI.. 2022 , 1	0
121	Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiology.	
120	Biobanking and Biomarkers in the Alzheimer's Disease Drug-Development Ecosystem. 2022 , 123-134	

119	A Multi-Dimensional Comparison of Alzheimer's Disease Neurodegenerative Biomarkers.. 2022,	
118	Plasma NFL is associated with mild cognitive decline in patients with diabetes.. 2022,	1
117	Waste Clearance in the Brain and Neuroinflammation: A Novel Perspective on Biomarker and Drug Target Discovery in Alzheimer's Disease.. 2022, 11,	0
116	Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments.. 2022, 12,	0
115	Associations between cerebrospinal fluid markers and cognition in aging and dementia: A systematic review.. 2022,	0
114	The Added Value of Cerebrospinal Fluid Neurofilament Light Chain to Existing Diagnostic Methods and Biomarkers in a Mixed Memory Clinic Cohort of Consecutive Patients.. 2022, 6, 121-127	0
113	Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review.. 2022, 14, 683689	1
112	Serum NFL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria.. 2022, 58,	0
111	Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.. 2022,	0
110	Vascular risk burden is a key player in the early progression of Alzheimer's disease.	
109	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.. 2021, 13, 199	2
108	Association of Cognitive Impairment With Free Water in the Nucleus Basalis of Meynert and Locus Coeruleus to Transentorhinal Cortex Tract.. 2021,	0
107	Blood-based biomarkers for Alzheimer's disease. 2021, e14408	7
106	Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies.. 2021, 15, 791670	1
105	Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment.	0
104	Post-Stroke Cognitive Impairment and Dementia.. 2022, 130, 1252-1271	9
103	Potential Protein Blood-Based Biomarkers in Different Types of Dementia: A Therapeutic Overview.. 2022,	1
102	Blood-Based Biomarkers for Alzheimer's Disease Diagnosis and Progression: An Overview.. 2022, 11,	0

101	Plasma Neurofilament Light Chain Levels Are Elevated in Children and Young Adults With Wolfram Syndrome.. 2022 , 16, 795317	0
100	Data_Sheet_1.doc. 2019 ,	
99	Table_1.doc. 2019 ,	
98	Image_1.tiff. 2020 ,	
97	Image_2.tiff. 2020 ,	
96	Image_3.tiff. 2020 ,	
95	Image_4.tiff. 2020 ,	
94	Image_5.tiff. 2020 ,	
93	Image_6.tiff. 2020 ,	
92	Table_1.DOCX. 2020 ,	
91	Table_1.XLSX. 2020 ,	
90	Blood biomarkers for Alzheimer's disease and related disorders.. 2022 ,	2
89	Clinical Application of Plasma Neurofilament Light Chain in a Memory Clinic: A Pilot Study.. 2022 , 21, 59-70	
88	Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI.. 2022 , 14, e12315	1
87	Fatty Acid-Binding Protein 7 (FABP-7), Glutamic Acid and Neurofilament Light Chain (NFL) as Potential Markers of Neurodegenerative Disorders in Psoriatic Patients-A Pilot Study.. 2022 , 11,	0
86	Alzheimer's Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint.. 2022 , 16, 837390	0
85	Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults.. 2022 , 116, 80-91	2
84	Evaluation of serum neurofilament light in the early management of mTBI patients.. 2022 ,	0

83	Recent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimer's Disease.. 2022 , 1	1
82	Neuronal ER-Signalosome Proteins as Early Biomarkers in Prodromal Alzheimer's Disease Independent of Amyloid- β Production and Tau Phosphorylation. 2022 , 15,	1
81	AI-Based Predictive Modelling of the Onset and Progression of Dementia. 2022 , 5, 700-714	
80	Association of Plasma Neurofilament Light Chain With Glycaemic Control and Insulin Resistance in Middle-Aged Adults. 13,	0
79	Linking Plasma Amyloid Beta and Neurofilament Light Chain to Intracortical Myelin Content in Cognitively Normal Older Adults. 14,	0
78	A multi-omics approach identifies a blood-based miRNA signature of cognitive decline in two large observational trials.	
77	Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment.	0
76	Acquired immunity and Alzheimer's disease. 2022 , 36, 1	
75	A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration. 2022 , 23, 7221	0
74	Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. 2022 , 17,	1
73	Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADE). 13,	0
72	The road to precision medicine: Eliminating the One Size Fits All Approach in Alzheimer's disease. 2022 , 153, 113337	1
71	Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer's disease. 2019 , 5, 94-105	
70	Inflammation Disrupts Cognitive Integrity via Plasma Neurofilament Light Chain Coupling Brain Networks in Alzheimer's Disease. 2022 , 1-14	
69	Alzheimer's disease: a scoping review of biomarker research and development for effective disease diagnosis.	0
68	Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer's disease. 2022 ,	1
67	The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.	7
66	Neurofilament light levels predict clinical progression and death in multiple system atrophy.	0

65	Plasma A β 2/40 ratio, p-tau181, GFAP, and NFL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.	1
64	Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease. 2022 , 14,	1
63	Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease. 14,	
62	Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease. 2022 , 10, 1869	0
61	Is liquid biopsy mature enough for the diagnosis of Alzheimer's disease?. 14,	1
60	The genetic and environmental etiology of blood-based biomarkers related to risk of Alzheimer's Disease in a population-based sample of early old-age men.	
59	Perioperative Neurofilament Light Plasma Concentrations and Cognition before and after Cardiac Surgery: A Prospective Nested Cohort Study. 2022 , 137, 303-314	0
58	Neurofilament light chain and S100B serum levels are associated with disease severity and outcome in patients with aneurysmal subarachnoid hemorrhage. 13,	0
57	Proteomic Markers and Early Prediction of Alzheimer's Disease. 2022 , 87, 762-776	
56	Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer's Disease. 2022 , 10, 1879	
55	Potential utility of plasma p-tau and NFL as surrogate biomarkers for preventive clinical trials.	0
54	Cerebral blood flow is associated with markers of neurodegeneration in Huntington's disease. 2022 , 102, 79-85	
53	Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer's disease. 2022 , 119, 1-7	
52	Anorexia Nervosa and Impact After Three Decades. 2022 , 1-17	0
51	Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: Mediation with hippocampal volume. 2022 , 14,	0
50	Biomarkers involved in the pathogenesis of cerebral small-vessel disease. 13,	0
49	Deamidation-related blood biomarkers show promise for early diagnostics of neurodegeneration.	0
48	A genetically modified minipig model for Alzheimer's disease with SORL1 haploinsufficiency. 2022 , 3, 100740	0

47	Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer's disease. 14,	0
46	Sustained Increase in Serum Glial Fibrillary Acidic Protein after First ST-Elevation Myocardial Infarction. 2022 , 23, 10304	2
45	Alzheimer's disease diagnosis by blood plasma molecular fluorescence spectroscopy (EEM). 2022 , 12,	1
44	Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease.	0
43	Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort. 10.1212/WNL.000000000201479	1
42	Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients. 2022 , 14,	1
41	Plasma brain injury markers are associated with volume status but not muscle health in heart failure patients. 2,	0
40	CSF 14-3-3's associated with tau pathology and elevated across the Alzheimer's disease continuum.	0
39	Association of cognitive function with Neurofilament light chain in the aqueous humor of human eye. 14,	0
38	Blood-based biomarkers for Alzheimer's disease. 2022 , 26, 10-14	1
37	Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene dose.	0
36	Association of Physical Activity With Neurofilament Light Chain Trajectories in Autosomal Dominant Frontotemporal Lobar Degeneration Variant Carriers.	0
35	Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges. 2022 ,	1
34	Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study. 2023 , 176, 105937	0
33	Blood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review. 089198872211416	0
32	Differential roles of A β 2/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring.	2
31	Association of neurofilament light chain with renal function: mechanisms and clinical implications. 2022 , 14,	0
30	CSF 14-3-3's associated with tau pathology and elevated across the Alzheimer's disease continuum.	0

- 29 Plasma Neurofilament Light Chain (NF-L) Is a Prognostic Biomarker for Cortical Damage Evolution but Not for Cognitive Impairment or Epileptogenesis Following Experimental TBI. **2022**, 23, 15208 2
- 28 Neurofilament light level correlates with brain atrophy, and cognitive and motor performance. 14, 0
- 27 Neuroprotective Effects of a Multi-Herbal Extract on Axonal and Synaptic Disruption in Vitro and Cognitive Impairment in Vivo. 1-26 0
- 26 Plasma biomarkers for neurodegenerative disorders: ready for prime time?. Publish Ahead of Print, 0
- 25 Lifelong exposure to high-altitude hypoxia in humans is associated with improved redox homeostasis and structural-functional adaptations of the neurovascular unit. 0
- 24 Neurofilament light (NFL) as biomarker in serum and CSF in status epilepticus. 0
- 23 Research and Prospect of Blood Biomarkers for Alzheimer’s Disease. **2023**, 13, 11-19 0
- 22 Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer’s Disease and Inhibitors of Amyloid Formation. **2023**, 13, 167 0
- 21 Deamidation-related blood biomarkers show promise for early diagnostics of neurodegeneration. **2022**, 10, 0
- 20 Predicting amyloid PET and tau PET stages with plasma biomarkers. 0
- 19 Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer’s disease. **2023**, 136, 505-521 0
- 18 Early Detection of Alzheimer’s Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers. **2023**, 92, 1077-1091 0
- 17 Diagnosis of Alzheimer’s disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. **2022**, 16, 25-39 0
- 16 The dynamics of plasma biomarkers across the Alzheimer’s continuum. **2023**, 15, 0
- 15 Development of ATR-FTIR spectroscopy for the diagnosis of Alzheimer’s disease using oral buccal cells. 0
- 14 Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer’s disease and synucleinopathies. **2023**, 187-218 0
- 13 A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques. **2023**, 18, 0
- 12 Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer’s Disease and Vascular Pathology. **2023**, 92, 887-898 0

- 11 Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. **2022**, 16, 25-39 ○
- 10 Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease. ○
- 9 Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample. **2023**, 15, ○
- 8 Association of cardiovascular risk factors and blood biomarkers with cognition: The HABS-HD study. **2023**, 15, ○
- 7 Accuracy of Raman spectroscopy in the diagnosis of Alzheimer’s disease. 14, ○
- 6 Anorexia Nervosa and Impact After Three Decades. **2023**, 469-485 ○
- 5 Examining four blood biomarkers for the detection of acute intracranial abnormalities following mild traumatic brain injury in older adults. 13, ○
- 4 Cerebral Small Vessel Disease Burden Predicts Neurodegeneration and Clinical Progression in Prodromal Alzheimer’s Disease. **2023**, 1-12 ○
- 3 Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease. **2023**, 15, ○
- 2 Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis. **2023**, 13, ○
- 1 Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease. **2023**, 15, ○